Author: hkaraman

Too often, companies delay commercial strategy until late-stage development, assuming it’s a downstream task. However, the vast majority, 80–90% of drugs in development, must prioritize biotech commercial planning much earlier than they think. Delaying commercial readiness can create compounding risks that threaten your funding, your timeline, and your launch success. 

Here’s what’s at stake when biotech commercial planning gets pushed too far down the road. 

1. Reduced Investor or Acquirer Interest 

Investors and acquirers today expect a robust early commercial strategy to accompany your clinical plan. Without a compelling commercial narrative, you risk being overlooked in favor of competitors who can clearly demonstrate product-market fit and growth potential. 

Biotech companies that delay commercial planning often struggle to: 

• Secure critical funding. 
• Attract interest from potential acquirers or partners. 
• Build credibility with key stakeholders. 

Biotech commercial planning isn’t a nice-to-have; it’s a prerequisite for investor confidence. 

 2. Misalignment with Market, Patients, and Payers 

If you wait too long to engage commercial functions, your development path may overlook critical market factors: 

• Is your product differentiated enough? 
• Will payers reimburse it? 
• Are you solving a true unmet need? 

Without early insights from market research and payer engagement, you risk launching a product that doesn’t resonate, or worse, one that doesn’t get covered. 

 3. Launch Delays 

A delayed start to commercial planning in biotech often creates major gaps: 

• Incomplete market understanding. 
• Lack of secondary data to support claims. 
• Underdeveloped KOL or HCP engagement plans. 

These gaps can delay your biotech product launch by months or even years, ultimately reducing the product’s lifetime value and competitive edge. 

 4. Costly Last-Minute Changes 

When commercial needs come into focus late, the resulting pivots are often expensive: 

• Retrofitting clinical trials. 
• Rushing to collect new data. 
• Overhauling messaging or branding at the eleventh hour. 

All of these emergency efforts drive up costs and reduce launch efficiency. By contrast, early biotech commercial planning allows you to integrate commercial considerations from the outset: saving time, money, and resources. 

 5. Underperformance at Launch 

Studies show that only 20–30% of first-time launchers meet or exceed commercial expectations. Why? It’s rarely the science. More often, it’s the absence of a well-structured, realistic commercial plan. 

Companies that invest in commercial readiness early are far better equipped to: 

• Navigate payer negotiations. 
• Educate physicians and patients. 
• Build internal capabilities that support long-term growth. 

The Takeaway: Plan Early, Win Bigger 

If you’re not developing a first-in-class or ultra-orphan drug, the market won’t give you much breathing room. For most companies, biotech commercial planning should begin in Phase 2 or earlier, not post-approval. 

By prioritizing early market insight, stakeholder alignment, and strategic planning, your team can reduce risk and maximize the return on years of clinical effort. 

Need guidance on when and how to start your biotech commercial planning? 

Our team specializes in helping biopharma teams build commercial strategies that scale with development. Connect with us today. 

The BIOSECURE Act, currently making its way through Congress, has the potential to create significant disruption across the U.S. biotechnology industry.

If enacted, BIOSECURE Act compliance will become mandatory for federally funded biotech companies, requiring them to sever ties with several key Chinese biotechnology firms. This shift could impact everything from R&D to supply chains, creating legal, operational, and financial risks for unprepared organizations. 

To ensure business continuity and reduce exposure, biotech leaders must begin preparing now. Here are five essential steps to build a BIOSECURE Act compliance strategy: 

BIOSECURE ACT Compliance Step #1: Assess Business Risks and Compliance Exposure  

Start by evaluating your organization’s current ties to restricted Chinese entities. 

1. Review dependencies across R&D, manufacturing, supply chains, and data storage. 
2. Identify any use of Chinese-owned technology or services. 
3. Engage legal counsel to analyze contract language and assess regulatory and legal liabilities. 

Being proactive helps reduce compliance gaps and mitigate enforcement risks. 

BIOSECURE ACT Compliance Step #2: Secure Intellectual Property and Mitigate Contract Risks

Strengthening your organization’s IP protections is a key part of BIOSECURE Act compliance. 

1. Take inventory of trade secrets, patents, and licensing agreements. 
2. Determine where IP relies on Chinese technology or vendors and assess alternatives. 
3. Revisit vendor contracts to evaluate termination clauses, financial penalties, and compliance triggers. 

This step ensures long-term IP security and shields your organization from unexpected legal or operational interruptions. 

BIOSECURE ACT Compliance Step #3: Diversify Vendors and Storage Strategies  

Reducing overreliance on Chinese partners is essential for BIOSECURE Act readiness. 

1. Identify and qualify alternate CDMOs and CROs in the U.S., India, Latin America, or the EU. 
2. Conduct due diligence on vendor capacity, certifications, and regulatory compliance. 
3. Set up redundant warehousing and distribution strategies to avoid bottlenecks. 

Vendor diversification will help ensure uninterrupted operations as the act’s provisions come into force. 

BIOSECURE ACT Compliance Step #4: Plan for Financial Impact and Transition Costs  

Complying with the BIOSECURE Act may require strategic financial planning. 

1. Estimate the full cost of vendor transitions, infrastructure updates, and regulatory adjustments. 
2. Compare the costs and benefits of onshoring vs. outsourcing to approved international vendors. 
3. Explore government incentives like tax credits, loan guarantees, and grants to offset costs. 
4. Prepare for potential countermeasures from China, including restrictions on biotech materials. 

BIOSECURE ACT Compliance Step #5: Protect Employees and Strengthen Cybersecurity  

BIOSECURE Act compliance also includes preparing for geopolitical risks. 

1. Create contingency plans for employees traveling to China, especially those at heightened risk under national security laws. 
2. Monitor updates from the U.S. State Department regarding travel and international trade risk. 
3. Bolster cybersecurity defenses to safeguard sensitive IP and company data from potential cyber threats or espionage. 

Stay Ahead of BIOSECURE Act Developments 

Even before the BIOSECURE Act becomes law, taking action now gives your organization a competitive advantage. Track updates to the Biotechnology Companies of Concern List and FAR regulations, and monitor whether additional countries are added to future legislation. 

Danforth Health’s compliance and risk management experts can guide you through this evolving landscape with practical, customized support. Contact us today. 

Preparing for a capital raise? A dynamic pro forma cap table is a must.

Private life science companies are nearly always looking towards their next financing event. Whether seed stage or Series C, stakeholders must understand in advance how their post-raise ownership might change based on wide-ranging assumptions, including the amount of their investment and the company’s current valuation. A pro forma cap table is used to model various outcomes to inform decision-making and set proper expectations before the deal is done. But one size does not fit all.

Pro forma cap table templates and services are abundant online, but they produce static statements that fall short of revealing the most accurate picture in real time. They don’t account for the full range or complexity of possible inputs, such as dilution protection for current shareholders or pre-existing convertible notes. In contrast, Danforth offers a dynamic, customized pro forma cap table that can reveal all possible outcomes, in real time, with the assuredness required by company founders and leaders, directors, shareholders and prospective investors.

How We Help

• An expertly-built tool – Designed and customized by experts in financial planning and analysis with many decades of experience in modeling for life science financings and related negotiations.
• Dynamic capability – Inputs can be added or changed as new or existing shareholders make commitments, providing real-time data throughout the financing process.
• Flexible delivery – Clients can choose to run the tool themselves or have our team create and run the tool on their behalf as a managed service.  
• Fail-safe measures – Quality control is built into the tool to ensure accuracy and ease of use.
• Longer-term view – We understand the legal and other requirements that drive how to format, round and structure the pro-forma to transition smoothly from the pre-financing model to the pro forma cap table and ultimately to the post-financing cap table.